Articles
The short answer is that nobody knows, and anyone who gives you a date is guessing. What can be said is which steps have to happen first, and how far along each one is. As of November 2026 the Ozempic litigation has no settlement, no trial dates, and one major ruling still outstanding.
Lost Vision While Taking Ozempic or Another GLP-1 Drug?
You may have a claim if all three are true:
- You took Ozempic, Wegovy, Mounjaro or another GLP-1 drug by prescription, not a compounded or gray-market version.
- You were diagnosed with NAION or had sudden, painless vision loss in one eye.
- The vision loss came after you started the drug.
Call 866-837-1010 or send us a message. The review is free. We review vision loss claims only and are not taking stomach paralysis cases.
There Are Two Ozempic Cases, and They Are at Different Stages
- Stomach and bowel injuries (MDL 3094): 4,082 lawsuits as of November 2, 2026, over gastroparesis, ileus and bowel obstruction.
- Vision loss (MDL 3163): 278 lawsuits over NAION, a sudden and usually permanent loss of sight. This MDL was created in December 2025.
Both are before Judge Karen S. Marston in federal court in Philadelphia. Our Ozempic vision loss lawsuit page covers the vision cases in detail.
What Has to Happen Before the Stomach Cases Can Settle
First, the court has to rule on the experts. The drugmakers moved to exclude the plaintiffs’ general-causation experts. The hearing ran September 14 through 18, 2026, and closing arguments were held October 13. As of November 12, no ruling has been reported. Status conferences are set for November 17 and December 15.
If the drugmakers win, most of the stomach cases likely end without any settlement. If the plaintiffs win, the court would then pick early cases for trial. No trial dates exist. In litigation like this, serious settlement talks usually follow rulings like these or the first verdicts, not before.
What Has to Happen Before the Vision Cases Can Settle
The vision cases are earlier in the process. The court held a Science Day in June 2026, and on July 2, 2026 it ordered early discovery and briefing on general causation and on whether the warnings were adequate. On November 9, 2026, the FDA required a NAION warning on every GLP-1 drug label. That helps the plaintiffs argue a warning was needed. It does not decide whether the drugs cause NAION, and it does not put a settlement on the calendar.
What Could Speed It Up or Slow It Down
- The expert ruling. A ruling for the plaintiffs raises the pressure to settle. A ruling for the drugmakers could end most stomach claims.
- Trial dates. Companies tend to negotiate when a jury is close.
- Appeals. Either side can appeal a major ruling, which adds time.
- New science and label changes, like the FDA’s November 2026 action.
Your Deadline Does Not Wait for a Settlement
There is no class action, so nothing preserves your claim while you wait. State law sets the deadline. Tennessee generally allows one year, and Alabama and Georgia generally allow two. Our Ozempic lawsuit update tracks the rulings, and our post on Ozempic lawsuit settlement amounts explains why no real number exists yet.
Talk With an Ozempic Lawyer
Fob & Foster Personal Injury Lawyers review Ozempic and GLP-1 vision loss claims at no charge. We are not taking stomach paralysis cases. Call 866-837-1010 or send us a message. There is no fee unless we recover for you.
Frequently Asked Questions
When will the Ozempic lawsuit be settled?
No one knows, and it will not be soon. No settlement talks have been announced, no trial dates are set, and the court has not yet ruled on whether the plaintiffs’ experts in the stomach and bowel cases may testify.
Has anyone been paid in the Ozempic lawsuit?
No. There is no settlement and no verdict in either federal case as of November 2026.
Does the FDA’s new vision loss warning mean a settlement is coming?
Not by itself. The November 9, 2026 label requirement supports the plaintiffs’ argument that a warning was needed, but the FDA did not find that the drugs cause NAION, and the drugmakers deny the claims.

